What is HC Wainwright’s Estimate for TPST FY2025 Earnings?

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Stock analysts at HC Wainwright raised their FY2025 earnings estimates for shares of Tempest Therapeutics in a report issued on Thursday, January 22nd. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($6.10) per share for the year, up from their previous forecast of ($12.78). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2025 earnings at ($0.62) EPS, FY2026 earnings at ($2.76) EPS, FY2027 earnings at ($2.28) EPS and FY2028 earnings at ($2.13) EPS.

A number of other research analysts also recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempest Therapeutics in a research note on Monday, December 29th. Wall Street Zen upgraded Tempest Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 11th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $12.50.

Tempest Therapeutics Trading Down 2.9%

Shares of NASDAQ TPST opened at $2.98 on Monday. The firm has a market capitalization of $14.69 million, a P/E ratio of -0.30 and a beta of -2.43. The firm’s 50-day moving average price is $3.31 and its 200-day moving average price is $7.25. Tempest Therapeutics has a 1-year low of $2.40 and a 1-year high of $13.13.

Shares of Tempest Therapeutics are scheduled to split on the morning of Friday, January 30th. The 2-1 split was recently announced. The newly issued shares will be issued to shareholders after the market closes on Thursday, January 29th.

Tempest Therapeutics (NASDAQ:TPST) last issued its earnings results on Wednesday, November 5th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.27) by $2.48.

Institutional Investors Weigh In On Tempest Therapeutics

A hedge fund recently raised its stake in Tempest Therapeutics stock. Vanguard Group Inc. increased its stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the third quarter, according to its most recent filing with the SEC. The fund owned 162,560 shares of the company’s stock after buying an additional 27,952 shares during the quarter. Vanguard Group Inc. owned 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent quarter. 22.52% of the stock is owned by hedge funds and other institutional investors.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.